So in this study, we included individuals from the ALFA+ cohort. It is a cohort with a family history of AD or APOE for carriership. They are cognitively unimpaired and in comparison to the cohorts that are available in literature, they are in an earlier stage of pathology, and also they are much younger than what has been reported in literature, so which is kind of the value of this cohort. In this study, first, we wanted to understand if we are able to see tau PET signal in this early cohort and if they are following Braak stages, and what we observed is that in this early cohort, we were seeing a tau PET signal in the early stage of the pathology, and also they are following Braak stages...
So in this study, we included individuals from the ALFA+ cohort. It is a cohort with a family history of AD or APOE for carriership. They are cognitively unimpaired and in comparison to the cohorts that are available in literature, they are in an earlier stage of pathology, and also they are much younger than what has been reported in literature, so which is kind of the value of this cohort. In this study, first, we wanted to understand if we are able to see tau PET signal in this early cohort and if they are following Braak stages, and what we observed is that in this early cohort, we were seeing a tau PET signal in the early stage of the pathology, and also they are following Braak stages. I should also mention that the prevalence of tau PET pathology in this subsample is, of course, lower compared as they are cognitively unimpaired and they are at risk of AD. In the next step, we wanted to understand what’s the association between tau PET signal and fluid biomarkers. So in general, what we observed is that we saw a strong association, especially between tau PET in early tau PET Braak 1-2 and also metatemporal ROI with CSF p-tau-217 and plasma p-tau-217 and other p-tau epitopes. But what is really important here after doing a ROC analysis, we observed that this plasma biomarker focusing on plasma p-tau-217 doesn’t have high positive predictive values in this cognitively unimpaired cohort. However, they have good negative predictive value. So what it means that when we have a cognitively unimpaired individual, plasma p-tau-217 can be useful for ruling out the presence of tau pathology. But if we want to understand and to detect the presence of tau pathology, we definitely need more additional tools like CSF or tau PET scans.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
